1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
66E32C021A2A9E6B36525789C004834FC
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/6E32C021A2A9E6B36525789C004834FC!OpenDocument
18
19OpenDocument
2018.97.14.85
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25SPCL




» Products & Services » » Product Launch » Market Entry: Metabolic and Cardiovascular Diseases

Complimentary Excerpt: Resource Allocation and Launch Readiness Factors that Shape a Strong Cardiovascular Market Entry: Stakeholder Allocations, Investment Levels and Resource Levels Across Launch Functions

ID: MD-243


Pages: 4


Published: Pre-2019


Delivery Format: Online


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS

To download this excerpt, click "
Buy Now".


To return to the study abstract to purchase the full study -
click here

This excerpt includes research findings and metrics from document #5131 "Resource Allocation and Launch Readiness Factors that Shape a Strong Cardiovascular Market Entry: Stakeholder Allocations, Investment Levels and Resource Levels Across Launch Functions."


Industries Profiled:
Pharmaceutical; Biotech; Medical Device; Health Care; Chemical; Manufacturing; Consumer Products; Diagnostic; Media


Companies Profiled:
Abbott Laboratories; Amgen; Actelion; AstraZeneca; GlaxoSmithKline; Bristol-Myers Squibb; Roche; Lilly; Novartis; Merck; Genentech; MedImmune; Bayer; Cephalon; Inc.; Teva Neuroscience; Novo Nordisk; Amylin; Laboratorios Deramtologicos Darier; IDS Canada; UCB Pharma; Quintiles; Ther-Rx; ProCaps Laboratories; Baxter Healthcare; Synapse biomedical; Talecris; Eisai; Shire; Takeda Pharmaceuticals